Cytokines in chronic respiratory diseases

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Atamas, Sergei P ^a,b   Chapoval, Svetlana P ^a   Keegan, Achsah D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BEVACIZUMAB; CANAKINUMAB; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; EOTAXIN; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 25; INTERLEUKIN 32; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 8; ONCOSTATIN M; PLATELET DERIVED GROWTH FACTOR; PTK 737; RANTES; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; EOSINOPHIL; FIBROBLAST; HELPER CELL; HUMAN; IMMUNOTHERAPY; LUNG FIBROSIS; TH2 CELL;

EID: 84875152978     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.3410/B5-3     Document Type: Article

References (212)

1. Zhu J, Paul WE: CD4 T cells: fates, functions, and faults. Blood 2008, 112: 1557-69.
2. Busse WW, Rosenwasser LJ: Mechanisms of asthma. The Journal of allergy and clinical immunology 2003, I I I : S799-804.
3. Bhakta NR, Woodruff PG: Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev 2011, 242: 220-32.
4. Wenzel SE: Asthma phenotypes: the evolution from clinical to molecular approaches. Nature medicine 2012, 18: 716-25.
5. Wills-Karp M: lnterleukin-13 in asthma pathogenesis. Immunol Rev 2004, 202: 175-90.
6. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA: Role of breast regression protein 39 (BRP-39)/chitinase 3-like-l in Th2 and IL-13-induced tissue responses and apoptosis. The Journal of experimental medicine 2009, 206: 1149-66.
7. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD, Castro M, Polineni D, Patterson GA, Schwendener RA, Allard JD, Peltz G, Holtzman MJ: Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nature medicine 2008, 14: 633-40.
8. Melgert BN, Oriss TB, Qi Z, Dixon-McCarthy B, Geerlings M, Hylkema MN, Ray A: Macrophages: regulators of sex differences in asthma? American journal of respiratory cell and molecular biology 2010, 42: 595-603.
9. Melgert BN, ten Hacken NH, Rutgers B, Timens W, Postma DS, Hylkema MN: More alternative activation of macrophages in lungs of asthmatic patients. The Journal of allergy and clinical immunology 2011, 127: 831-3.
10. Subrata LS, Bizzintino J, Mamessier E, Bosco A, McKenna KL, Wikstrom ME, Goldblatt J, Sly PD, Hales BJ, Thomas WR, Laing IA, Le Souëf PN, Holt PG: Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol 2009, 183: 2793-800.
11. Ford AQ, Dasgupta P, Mikhailenko I, Smith EM, Noben-Trauth N, Keegan AD: Adoptive transfer of IL-4Ralpha(+) macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation. BMC Immunol 2012, 13: 6.
12. Dasgupta P, Keegan AD: Contribution of Alternatively Activated Macrophages to Allergic Lung Inflammation: A Tale of Mice and Men. J Innate Immun 2012, 4: 478-88.
13. Luzina IG, Lockatell V, Lavania S, Pickering EM, Kang PH, Bashkatova YN, Andreev SM, Atamas SP: Natural production and functional effects of alternatively spliced interleukin-4 protein in asthma. Cytokine 2012, 58: 20-6.
14. Luzina IG, Lockatell V, Todd NW, Highsmith K, Keegan AD, Hasday JD, Atamas SP: Alternatively spliced variants of interleukin-4 promote inflammation differentially. J Leukoc Biol 2011, 89: 763-70.
15. Lužina IG, Lockatell V, Todd NW, Keegan AD, Hasday JD, Atamas SP: Splice isoforms of human interleukin-4 are functionally active in mice in vivo. Immunology 2011, 132: 385-93.
16. Heller NM, Dasgupta P, Dorsey NJ, Chapoval SP, Keegan AD: The type I and type Il receptor complexes for IL-4 and IL-13 differentially regulate allergic lung inflammation. In Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment. Edited by Pereira C. Rijeca, Croatia: InTECH; 2012: 43-82.
17. Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME: Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha I and the type Il IL-4 receptor in asthma pathogenesis. Proč Natí Acad Sa USA 2008, 105:7240-5. (Pubitemid 351754462)
18. Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS, Stevens S, Valenzuela DM, Murphy AJ, Yancopoulos GD, Urban JF Jr, Donnelly RP, Wynn TA: Unique functions of the type Il interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha I chain. Nat Immunol 2008, 9:25-33. (Pubitemid 350286200)
19. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA: Recombinant human interleukin 5 is a selective activator of human eosinophil function. The Journal of experimental medicine 1988, 167:219-24. (Pubitemid 18093705)
20. Foster PS, Hogan SP, Ramsay AJ, Matthaei Kl, Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. The Journal of experimental medicine 1996, 183:195-201. (Pubitemid 26028759)
21. Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, Brenneise IE, Horton MA, Haczku A, Gelfand EW, Leikauf GD, Lee NA: lnterleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. The Journal of experimental medicine 1997, 185: 2143-56. (Pubitemid 27265998)
22. Hamelmann E, Oshiba A, Loader J, Larsen GL, Gleich G, Lee J, Gelfand EW: Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. American journal of respiratory and critical care medicine 1997, 155:819-25. (Pubitemid 27133388)
23. Sur S, Gleich GJ, Swanson MC, Bartemes KR, Broide DH: Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. The Journal of allergy and clinical immunology 1995, 96: 661 -8.
24. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000, 356: 2144-8.
25. Stirling RG, van Rensen EL, Barnes PJ, Chung KF: lnterleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. American journal of respiratory and critical care mediane 2001, 164: 1403-9.
26. Lambrecht BN, Hammad H: Biology of lung dendritic cells at the origin of asthma. Immunity 2009, 31: 412-24.
27. Kool M, Hammad H, Lambrecht BN: Cellular networks controlling Th2 polarization in allergy and immunity. FI000 Biol Rep 2012, 4: 6.
28. Angkasekwinai P, Park H, Wang YH, Chang SH, Corry DB, Liu YJ, Zhu Z, Dong C: lnterleukin 25 promotes the initiation of proallergic type 2 responses. The Journal of experimental medicine 2007,204:1509-17. (Pubitemid 47048018)
29. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA: IL-33, an interleukin-l-like cytokine that signals via the IL-I receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-90. (Pubitemid 41587888)
30. Iseki M, Omori-Miyake M, Xu W, Sun X, Takaki S, Rawlings DJ, Ziegler SF: Thymic stromal lymphopoietin (TSLP)-induced polyclonal B-cell activation and autoimmunity are mediated by CD4+ T cells and IL-4. Int Immunol 2012, 24: 183-95.
31. Okayama Y, Okumura S, Sagara H, Yuki K, Sasaki T, Watanabe N, Fueki M, Sugiyama K, Takeda K, Fukuda T, Saito H, Ra C: FcepsilonRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur Respir J 2009, 34: 425-35.
32. Omori M, Ziegler S: Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. J Immunol 2007, 178:1396-404. (Pubitemid 46154610)
33. Ying S, O'Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S, Gao Z, Shamji B, Edwards MJ, Lee TH, Corrigan CJ: Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol 2008, 181: 2790-8.
34. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, Menon S, Seymour B, Jackson C, Kung TT, Brieland JK, Zurawski SM, Chapman RW, Zurawski G, Coffman RL: New IL-17 family members promote ThI or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. ] Immunol 2002, 169: 443-53. (Pubitemid 34686166)
35. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN: House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nature medicine 2009, 15: 410-6.
36. Lužina IG, Pickering EM, Kopách P, Kang PH, Lockatell V, Todd NW, Papadimitriou JC, McKenzie AN, Atamas SP: Full-Length IL-33 Promotes Inflammation but not Th2 Response In Vivo in an ST2-lndependent Fashion. J Immunol 2012, 189: 403-10.
37. Komai-Koma M, Xu D, Li Y, McKenzie AN, Mclnnes IB, Liew FY: IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007, 37:2779-86. (Pubitemid 47578297)
38. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, de Waal Malefyt R: Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011, 23: 307-15.
39. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, GutierrezRamos JC, Levinson D, Radbruch A, Kamradt T: TI/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proč Natl Acad Sd U S A 1998, 95:6930-5. (Pubitemid 28278084)
40. Nawijn MC, Dingjan GM, Ferreira R, Lambrecht BN, Karis A, Grosveld F, Savelkoul H, Hendriks RW: Enforced expression of GATA-3 in transgenic mice inhibits Th I differentiation and induces the formation of a TI/ST2-expressing Th2-committed T cell compartment in vivo. J Immunol 2001, 167:724-32. (Pubitemid 32660825)
41. Meisel C, Bonhagen K, Lohning M, Coyle AJ, Gutierrez-Ramos JC, Radbruch A, Kamradt T: Regulation and function of TI/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by TI/ST2 cross-linking. J Immunol 2001, 166:3143-50. (Pubitemid 33117311)
42. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, Ottoson P, Persson P, Delaney T, Lehar S, Lin S, Poisson L, Meisel C, Kamradt T, Bjerke T, Levinson D, Gutierrez-Ramos JC: Crucial role of the interleukin I receptor family member Tl /ST2 in T helper cell type 2-mediated lung mucosal immune responses. The Journal of experimental medicine 1999, 190:895-902. (Pubitemid 29480818)
43. WaIzI G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw PJ, Hussell T: Inhibition of TI/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 CThI)but not Th I-driven immunopathology. The Journal of experimental medicine 2001, 193: 785-92.
44. Townsend MJ, Fallon PG, Matthews DJ, JoNn HE, McKenzie AN: TI/ST2-deficient mice demonstrate the importance of TI/ST2 in developing primary T helper cell type 2 responses. The Journal of experimental medicine 2000, 191: 1069-76.
45. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jonn HE, McKenzie AN: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464: 1367-70.
46. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fujii H, Koyasu S: Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1 (+) lymphoid cells. Nature 2010, 463: 540-4.
47. Saenz SA, Siracusa MC, Perrigoue JG, Spencer SP, Urban JF Jr., Tocker JE, Budelsky AL, Kleinschek MA, Kastelein RA, Kambayashi T, Bhandoola A, Artis D: IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010, 464: 1362-6.
48. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, Loe ksley RM: Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proč Natí Acad Sci U S A 2010, 107: 11489-94.
49. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, McKenzie AN: Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. The Journal of allergy and clinical immunology 2012, 129: 191-8 e 191 -4.
50. Wang YH, lto T, Homey B, Watanabe N, Martin R, Barnes CJ, Mclntyre BW, Gilliet M, Kumar R, Yao Z, Liu YJ: Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 2006, 24: 827-38.
51. Ying S, O'Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, Robinson D, Zhang G, Zhao J, Lee TH, Corrigan C: Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005, 174:8183-90. (Pubitemid 40806330)
52. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ: A role for TSLP in the development of inflammation in an asthma model. The Journal of experimental mediane 2005, 202: 829-39.
53. Li YL, Li HJ, Ji F, Zhang X, Wang R, Hao JQ, Bi WX, Dong L: Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. The Journal of asthma: official journal of the Association for the Care of Asthma 2010, 47: 117-23.
54. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID: Evidence of a role of tumor necrosis factor alpha in refractory asthma. The New England journal of medicine 2006, 354:697-708. (Pubitemid 43247140)
55. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012-8. (Pubitemid 41705469)
56. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M, Woods J, May R, Sleeman MA, Anderson IK, Brightling CE: Expression of the T helper 17-associated cytokines IL-I7A and IL-I7F in asthma and COPD. Chest 2010, 138: 1140-7.
57. Willart MA, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN, Hammad H: Interleukin-lalpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. The Journal of experimental medicine 2012, 209: 1505-17.
58. Schmitz N, Kurrer M, Kopf M: The IL-I receptor I is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 2003, 33:991-1000. (Pubitemid 36546687)
59. Saha S, Doe C, Mistry V, Siddiqui S, Parker D, Sleeman M, Cohen ES, Brightling CE: Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax 2009, 64: 671-6.
60. Yamashita N, Tashimo H, lshida H, Kaneko F, Nakano J, Kato H, Hirai K, Horiuchi T, Ohta K: Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol 2002, 219:92-7. (Pubitemid 36259613)
61. Vrugt B, Wilson S, Bron A, Holgate ST, Djukanovic R, Aalbers R: Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J 2000, 15:1014-21. (Pubitemid 30399269)
62. Hoshino M, Nakamura Y, Hamid QA: Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. The Journal of allergy and clinical immunology 2001, 107:1034-8. (Pubitemid 32523344)
63. Chapoval SP, Lee CG, Tang C, Keegan AD, Cohn L, Bottomly K, Elias JA: Lung vascular endothelial growth factor expression induces local myeloid dendritic cell activation. Clin Immunol 2009, 132: 371-84.
64. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM, Elias JA: Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nature medicine 2004, 10:1095-103. (Pubitemid 39424871)
65. Harada M, Obara K, Hirota T, Yoshimoto T, Hitomi Y, Sakashita M, Doi S, Miyatake A, Fujita K, Enomoto T, Taniguchi M, Higashi N, Fukutomi Y, Nakanishi K, Nakamura Y, Tamari M: A functional polymorphism in IL-18 is associated with severity of bronchial asthma. American journal of respiratory and critical care medicine 2009, 180: 1048-55.
66. Wild JS, Sigounas A, Sur N, Siddiqui MS, Alam R, Kurimoto M, Sur S: IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol 2000, 164:2701-10. (Pubitemid 30115503)
67. Bellini A, Marini MA, Bianchetti L, Barczyk M, Schmidt M, Mattoli S: lnterleukin (IL)-4, IL-13, and IL-I7A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal immunology 2012, 5: 140-9.
68. Nakajima H, Hirose K: Role of IL-23 and Th 17 Cells in Airway Inflammation in Asthma. Immune network 2010, 10: 1-4.
69. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines.The Journal of allergy and clinical immunology 2001, 108:430-8. (Pubitemid 32881066)
70. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, Moles JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gasean H: Chronically inflamed human tissues are infiltrated by highly differentiated Th 17 lymphocytes. J Immunol 2008, 180: 7423-30.
71. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens JL: IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respiratory research 2006, 7: 135.
72. Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th 17 Cells. Annual review of immunology 2009, 27: 485-517.
73. Redhu NS, Gounni AS: Function and mechanisms of TSLP/ TSLPR complex in asthma and COPD. Clin Exp Allergy 2012, 42: 994-1005.
74. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, KoIIs JK: TH 17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008, 181: 4089-97.
75. Palmqvist C, Wardlaw AJ, Bradding P: Chemokines and their receptors as potential targets for the treatment of asthma. BrJ Pharmacol 2007, 151 (6):725-736. (Pubitemid 47075313)
76. Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA: Novel biomarkers in asthma: chemokines and chitinase-like proteins. Curr Opin Allergy Clin Immunol 2009, 9: 60-6.
77. Zeng R, Li C, Li N, Wei L, Cui Y: The role of cytokines and chemokines in severe respiratory syncytial virus infection and subsequent asthma. Cytokine 2011, 53: 1-7.
78. Rojas-Ramos E, Avalos AF, Perez-Fernandez L, Cuevas-Schacht F, Valencia-Maqueda E, Teran LM: Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4, and eotaxins-1 and -2 in childhood asthma. Eur RespirJ 2003, 22: 3 10-6.
79. Schuh JM, Blease K, Hogaboam CM: The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice. Faseb 2002, 16: 228-30.
80. Alam R, YorkJ, Boyars M, Stafford S, GrantJA, Lee J, Forsythe P, Sim T, Ida N: Increased MCP-I, RANTES, and MIP-1 alpha in bronchoalveolar lavage fluid of allergic asthmatic patients. American journal of respiratory and critical care medicine 1996, 153:1398-404. (Pubitemid 26112608)
81. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB: Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. Immunol 1999, 163: 6321-9.
82. Ravensberg AJ, Ricciardolo FL, van Schadewijk A, Rabe KF, Sterk PJ, Hiemstra PS, Mauad T: Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. The Journal of allergy and clinical immunology 2005, 115: 779-85.
83. Dent G, Hadjicharalambous C, Yoshikawa T, Handy RL, Powell J, Anderson IK, Louis R, Davies DE, Djukanovic R: Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. American journal of respiratory and critical care medicine 2004, 169: 11 10-7.
84. Nakamura H, Weiss ST, Israel E, Luster AD, Dražen JM, Lilly CM: Eotaxin and impaired lung function in asthma. American journal of respiratory and critical care medicine 1999, 160:1952-6. (Pubitemid 30004702)
85. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV: Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. American journal of respiratory and critical care medicine 2000, 161: 1 185-90.
86. John AE, Zhu YM, Brightling CE, Pang L, Knox AJ: Human airway smooth muscle cells from asthmatic individuals have CXCL8 hypersecretion dueto increased NF-kappaB p65, C/EBP beta, and RNA polymerase Il binding to the CXCL8 promoter. J Immunol 2009, 183: 4682-92.
87. Cho SH, Stanciu LA, Holgate ST, Johnston SL: Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma. American journal of respiratory and critical care medicine 2005, 171: 224-30.
88. Brooks GD, Buchta KA, Swenson CA, GernJE, Busse WW: Rhinovirusinduced interferon-gamma and airway responsiveness in asthma. American journal of respiratory and critical care medicine 2003, 168:1091-4. (Pubitemid 37338938)
89. Kobayashi M, Ashino S, Shiohama Y, Wakita D, Kitamura H, Nishimura T: IFN-gamma elevates airway hyper-responsiveness via up-regulation of neurokinin A/neurokinin-2 receptor signaling in a severe asthma model. Eur J Immunol 2012, 42: 393-402.
90. Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. American journal of respiratory and critical care medicine 1996, 153: 530-4.
91. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE: Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2001, 163:349-55. (Pubitemid 32158511)
92. Kang MJ, Choi JM, Kim BH, Lee CM, Cho WK, Choe G, Kim DH, Lee CG, Elias JA: IL-18 induces emphysema and airway and vascular remodeling via IFN-gamma, IL-17A, and IL-13. American journal of respiratory and critical care medicine 2012, 185: 1205-17.
93. Kaur M, Smyth LJ, Cadden P, Grundy S, Ray D, Plumb J, Singh D: T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease. Respiratory research 2012, 13: 20.
94. Moermans C, Heinen V, Nguyen M, Henket M, Sele J, Manise M, Corhay JL, Louis R: Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine 2011, 56: 298-304.
95. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, Stockley RA: Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 2009, 29: 508-16.
96. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ: High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med 2003, 97:1299-302. (Pubitemid 37526998)
97. Di Stefano A, Capelli A, Donner CF: Role of interleukin-8 in the pathogenesis and treatment of COPD. Chest 2004, 126:676-8. (Pubitemid 39258016)
98. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK: Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2003, 168:968-75. (Pubitemid 37267175)
99. Schulz C, Kratzel K, Wolf K, Schroll S, Köhler M, Pfeifer M: Activation of bronchial epithelial cells in smokers without airway obstruction and patients with COPD. Chest 2004, 125:1706-13. (Pubitemid 38648401)
100. Perng DW, Huang HY, Chen HM, Lee YC, Perng RP: Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 2004, 126: 375-81.
101. DamiaAde D, Gimeno JC, Ferrer MJ, Fabregas ML, Folch PA, Paya JM: A study of the effect of proinflammatory cytokines on the epithelial cells of smokers, with or without COPD. Archivos de bronconeumologia 2011, 47: 447-53.
102. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ: Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003, 123:1240-7. (Pubitemid 36444384)
103. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T, Kato S, Iwasaki H, Watanabe K, Aizawa H: Interleukin-18 production and pulmonary function in COPD. Eur Respir J 2008, 31: 287-97.
104. Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX, Chensue SW, Polak TJ, Sonstein J, Todt JC, Ames TM, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL: Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15. J Immunol 2010, 184: 6504-13.
105. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, Sfriso P, Balestro E, Dinarello CA, Saetta M: IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2008, 178: 894-901.
106. Eustace A, Smyth LJ, Mitchell L, Williamson K, Plumb J, Singh D: Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. Chest 2011, 139: 1089-100.
107. Chang Y, Nadigel J, Boulais N, Bourbeau J, Maltais F, Eidelman DH, Hamid Q: CDS positive T cells express IL-17 in patients with chronic obstructive pulmonary disease. Respiratory research 2011, 12: 43.
108. Vargas-Rojas Ml, Ramirez-Venegas A, Limon-Camacho L, Ochoa L, Hernandez-Zenteno R, Sansores RH: Increase of Th 17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med 2011, 105: 1648-54.
109. Zhang X, Zheng H, Zhang H, Ma W, Wang F, Liu C, He S: Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke. Cytokine 2011, 56: 717-25.
110. de Boer Wl, van Schadewijk A, Sont JK, Sharma HS, StolkJ, Hiemstra PS, van Krieken JH: Transforming growth factor beta I and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 1998, 158: 1951 -7.
111. Takizawa H, Tanaka M, Takami K, Ohtoshi T, lto K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A: Increased expression of ransforming growth factor-beta I in small airway epithelium rom tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). American journal of respiratory and critical care medicine 2001, 163:1476-83. (Pubitemid 32506619)
112. Kokturk N, Tatlicioglu T, Memis L, Akyurek N, Akyol G: Expression of transforming growth factor beta I in bronchial biopsies in asthma and COPD. The Journal of asthma : official journal of the Association for the Care of Asthma 2003, 40: 887-93.
113. Soltani A, Sohal SS, Reid D, Weston S, Wood-Baker R, Walters EH: Vessel-Associated Transforming Growth Factor-Beta I (TGFbetal) Is Increased in the Bronchial Reticular Basement Membrane in COPD and Normal Smokers. PLoS One 2012, 7: e39736.
114. Baarsma HA, Spanjer Al, Haitsma G, Engelbertink LH, Meurs H, Jonker MR, Timens W, Postma DS, Kerstjens HA, Gosens R: Activation of WNT/beta-catenin signaling in pulmonary fibroblasts by TGF-beta(l) is increased in chronic obstructive pulmonary disease. PLoS One 2011, 6: e25450.
115. Ichimaru Y, Krimmer Dl, Burgess JK, Black JL, Oliver BG: TGFbeta enhances deposition of perlecan from COPD airway smooth muscle. American journal of physiology Lung cellular and molecular physiology 2012, 302: L325-33.
116. Steen VD, Medsger TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66: 940-4.
117. Ley B, Collard HR, King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. American journal of respiratory and critical care mediane 2011, 183: 431-40.
118. Grieb G, Steffens G, Pallua N, Bernhagen J, Bucala R: Circulating fibrocytes-biology and mechanisms in wound healing and scar formation. Int Rev Cell MoI Biol 2011, 291: 1-19.
119. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B: The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009, 86: 1111-8.
120. Herzog EL, Bucala R: Fibrocytes in health and disease. Exp Hematol 2010, 38: 548-56.
121. Tanjore H, Blackwell TS, Lawson WE: Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. American journal of physiology Lung cellular and molecular physiology 2012, 302: L72l-9.
122. King TE Jr., Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011, 378: 1949-61.
123. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta I: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005, 166:1321-32. (Pubitemid 40586504)
124. Homer RJ, Elias JA, Lee CG, Herzog E: Modern concepts on the role of inflammation in pulmonary fibrosis. Arch Pathol Lab Med 2011, 135: 780-8.
125. Bringardner BD, Baran CP, Eubank TD, Marsh CB: The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 2008, 10: 287-301.
126. Chambers RC: Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? BrJ Pharmacol 2008, 153: S367-78.
127. Lužina IG, Todd NW, Nacu N, Lockatell V, Choi J, Hummers LK, Atamas SP: Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbetaS on pulmonary T lymphocytes. Arthritis Rheum 2009, 60: 1530-9.
128. Mozaffarian A, Brewer AW, Trueblood ES, Lužina IG, Todd NW, Atamas SP, Arnett HA: Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008, 181: 7243-53.
129. Lužina IG, Todd NW, lacono AT, Atamas SP: Roles of T lymphocytes in pulmonary fibrosis. J Leukoc Biol 2008, 83:237-44. (Pubitemid 351225603)
130. Pochetuhen K, Lužina IG, Lockatell V, Choi J, Todd NW, Atamas SP: Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol 2007, 171:428-37. (Pubitemid 47344676)
131. Kliment CR, Oury TD: Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radie Biol Med 2010, 49: 707-17.
132. Kinnula VL, Fattman CL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. American journal of respiratory and critical care medicine 2005, 172:417-22. (Pubitemid 41117386)
133. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ: NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nature mediane 2009, 15: 1077-81.
134. Dancer RC, Wood AM, Thickett DR: Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011, 38: 1461-7.
135. Garcia-Alvarez J, Ramirez R, Sampieri CL, Nuttall RK, Edwards DR, Selman M, Pardo A: Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis. Sarcoidosis Vase Diffuse Lung Dis 2006, 23:13-21. (Pubitemid 44259205)
136. Tan RJ, Fattman CL, Niehouse LM, Tobolewski JM, Hanford LE, Li Q, Monzón FA, Parks WC, Oury TD: Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. American journal of respiratory cell and molecular biology 2006, 35:289-97. (Pubitemid 44353396)
137. Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Mäher TM, Nicholson AG, Moffatt JD, Laurent GJ, Derian CK, Eickelberg O, Chambers RC: Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. The Journal of clinical investigation 2009, 119: 2550-63.
138. Mercer PF, Johns RH, Scotton CJ, Krupiczojc MA, Konigshoff M, Howell DC, McAnulty RJ, Das A, Thorley AJ, Tetley TD, Eickelberg O, Chambers RC: Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. American journal of respiratory and critical care medicine 2009, 179: 414-25.
139. Bauman KA, Wettlaufer SH, Okunishi K, Vannella KM, Stoolman JS, Huang SK, Courey AJ, White ES, Hogaboam CM, Simon RH, Toews GB, Sisson TH, Moore BB, Peters-Golden M: The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. The Journal of clinical investigation 2010, 120: 1950-60.
140. Chambers RC, Laurent GJ: Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans 2002, 30: 194-200.
141. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J, Silver RM: Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011, 63: 1416-25.
142. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J: Adenovectormediated gene transfer of active transforming growth factorbeta I induces prolonged severe fibrosis in rat lung. The Journal of clinical investigation 1997, 100:768-76. (Pubitemid 27371693)
143. Sheppard D: Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. ProcAm Thome Soc 2006, 3: 413-7.
144. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay M A, Rifkin DB, Sheppard D: The integrin alpha v beta 6 binds and activates latent TGF beta I : a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96: 319-28.
145. HoranGS, Wood S, Ona V, Li DJ. Lukashev ME. Weinreb PH, Simon KJ, Hahm K, Allaire NE, Rinaldi NJ, Goyal J, Feghali-Bostwick CA, Matteson EL, O'Hara C, Lafyatis R, Davis GS, Huang X, Sheppard D, Violette SM: Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. American journal of respiratory and critical care medicine 2008, 177: 56-65.
146. Sheppard D: Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 2005, 24: 395-402.
147. Bonniaud P, Margetts PJ, KoIb M, Haberberger T, Kelly M, RobertsonJ, GauldieJ: Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis. American journal of respiratory and critical care medicine 2003, 168:770-8. (Pubitemid 37188299)
148. Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, Lindahl GE: Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 2009, 60: 2142-55.
149. Atamas SP, Lužina IG, Dai H, Wilt SG, White B: Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002, 168: 1 139-45.
150. Jakubzick C, Choi ES, Joshi BH, Keane MP, Kunkel SL, Puri RK, Hogaboam CM: Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells.) Immunol 2003, 171:2684-93. (Pubitemid 37025582)
151. Jakubzick C, Kunkel SL, Puri RK, Hogaboam CM: Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res 2004, 30:339-49. (Pubitemid 39546234)
152. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canónica GW, Jasmin C, Azzarone B: lnterleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. The Journal of clinical investigation 1998, 101:2129-39. (Pubitemid 28244097)
153. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. The Journal of clinical investigation 1999, 103:779-88. (Pubitemid 29152623)
154. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA: lnterleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(l). The Journal of experimental medicine 2001, 194:809-21. (Pubitemid 32983016)
155. Sempowski GD, DerdakS, Phipps RP: lnterleukin-4 and interferongamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996, 167: 290-6. (Pubitemid 26145862)
156. Jaffe HA, Gao Z, Mori Y, Li L, Varga J: Selective inhibition of collagen gene expression in fibroblasts by an interferongamma transgene. Exp Lung Res 1999, 25:199-215. (Pubitemid 29210659)
157. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, Kunkel SL: A role for C-C chemokines in fibrotic lung disease. JLeukocBiol 1995, 57: 782-7.
158. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta I gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271:17779-84. (Pubitemid 26250752)
159. Moore BB, Paine R, 3rd, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB: Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001, 167:4368-77. (Pubitemid 32954313)
160. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB: CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166:675-84. (Pubitemid 40315625)
161. Fritz DK, Kerr C, Fattouh R, Llop-Guevara A, Khan Wl, Jordana M, Richards CD: A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent.) Immunol 2011, 186: 1107-18.
162. Lo Re S, Lecocq M, Uwambayinema F, Yakoub Y, Delos M, Demoulin JB, Lucas S, Sparwasser T, Renauld JC, Lison D, Huaux F: Plateletderived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. American journal of respiratory and critical care medicine 2011, 184: 1270-81.
163. Trojanowska M: Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008, 47: v2-4.
164. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE, Huber PE: Inhibition of plateletderived growth factor signaling attenuates pulmonary fibrosis. The Journal of experimental medicine 2005, 201:925-35. (Pubitemid 40524462)
165. Lužina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B: Gene expression in bronchoalveolar lavage cells from scleroderma patients. American journal of respiratory cell and molecular biology 2002, 26:549-57. (Pubitemid 34315862)
166. Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Muller-Quernheim J: CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56:1685-93. (Pubitemid 46764100)
167. Pardo A, Smith KM, Abrams J, Coffman R, Bustos M, McClanahan TK, Grein J, Murphy EE, Zlotnik A, Selman M: CCLI8/DC-CK-I/PARC up-regulation in hypersensitivity pneumonitis. J Leukoc Biol 2001, 70: 610-6.
168. de Nadai P, Charbonnier AS, Chenivesse C, Senechal S, Fournier C, Gilet J, Vorng H, Chang Y, Gösset P, Wallaert B, Tonnel AB, Lassalle P, Tsicopoulos A: Involvement of CCL18 in allergie asthma. J Immunol 2006, 176: 6286-93.
169. Mrázek F, Sekerová V, Drábek J, Kolek V, du Bois RM, Petrek M: Expression of the chemokine PARC mRNA in bronchoalveolar cells of patients with sarcoidosis. Immunol Lett 2002, 84:17-22. (Pubitemid 34879915)
170. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G: A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCLI8. American journal of respiratory and critical care medicine 2006, 173: 781-92.
171. Atamas SP, Lužina IG, Choi J, TsymbalyukN, Carbonetti NH, Singh IS, Trojanowska M, Jimenez SA, White B: Pulmonary and activationregulated chemokine stimulates collagen production in lung fibroblasts. American journal of respiratory cell and molecular biology 2003, 29:743-9. (Pubitemid 38045942)
172. Lužina IG, Highsmith K, Pochetuhen K, Nacu N, Rao JN, Atamas SP: PKCalpha mediates CCLI8-stimulated collagen production in pulmonary fibroblasts. American journal of respiratory cell and molecular biology 2006, 35:298-305. (Pubitemid 44353397)
173. Lužina IG, Tsymbalyuk N, Choi J, Hasday JD, Atamas SP: CCL18stimulated upregulation of collagen production in lung fibroblasts requires SpI signaling and basal Smad3 activity. J Cell Physiol 2006, 206:221-8. (Pubitemid 41740735)
174. Lužina IG, Papadimitriou JC, Anderson R, Pochetuhen K, Atamas SP: Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum 2006, 54:2643-55. (Pubitemid 44205027)
175. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH: Bone marrowderived progenitor cells in pulmonary fibrosis. The Journal of dinical investigation 2004, 113: 243-52.
176. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. The Journal of clinical investigation 2004, 114: 438-46.
177. Xu J, Mora A, Shim H, Stecenko A, Brigham KL, Rojas M: Role of the SDF-I/CXCR4 axis in the pathogenesis of lung injury and fibrosis. American journal of respiratory cell and molecular biology 2007, 37:291-9. (Pubitemid 350067608)
178. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA: Bleomycin and IL-1 beta-mediated pulmonary fibrosis is IL-I7A dependent. The Journal of experimental medicine 2010, 207: 535-52.
179. LoRe S, Dumoutier L, Couillin l, VanVyve C, Yakoub Y, Uwambayinema F, Marien B, van den Brule S, Van Snick J, Uyttenhove C, Ryffel B, Renauld JC, Lison D, Huaux F: IL-l7A-producing gammadelta T and Th 17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol 2010, 184: 6367-77.
180. Mi S, Li Z Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W, Hu ZW: Blocking IL-I7A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta I -dependent and -independent mechanisms. J Immunol 2011, 187: 3003-14.
181. Sun L, Louie MC, Vannella KM, Wilke CA, LeVine AM, Moore BB, Shanley TP: New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. American journal of physiology Lung cellular and molecular physiology 2011, 300: L34l-53.
182. Garcia-Prieto E, Gonzalez-Lopez A, Cabrera S, Astudillo A, Gutierrez-Fernandez A, Fanjul-Fernandez M, Batalla-Solis E, Puente XS, Fueyo A, Lopez-Otin C, Albaiceta GM: Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10. PLoS One 2010, 5: el3242.
183. Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM, Keane MP: The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 2004, 173:4692-8. (Pubitemid 39280704)
184. Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J: Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. The Journal of clinical investigation 1996, 97: 1 102-10.
185. Xing Z, Tremblay GM, Sime PJ, Gauldie J: Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-beta I and myofibroblast accumulation. Am J Pathol 1997, 150:59-66. (Pubitemid 27027096)
186. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, McDonald R, Phare SM, Peters-Golden M, Paine R, 3rd, Toews GB: GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism.J Immunol 2000, 165:4032-9. (Pubitemid 32057315)
187. Atamas SP, White B: The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003, 15:772-7. (Pubitemid 38156306)
188. Atamas SP, White B: Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003, 14:537-50. (Pubitemid 37296026)
189. Atamas SP: Complex cytokine regulation of tissue fibrosis. Life Sci 2002, 72: 631-43.
190. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. The New England journal of mediane 2009, 360: 973-84.
191. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370: 1422-3 I.
192. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Zhou S, Raible D, O'Byrne PM: Effects of interleukin-13 blockade on allergeninduced airway responses in mild atopic asthma. American journal of respiratory and critical care medicine 2011, 183: 1007-14.
193. Maes T, Joos GF, Brusselle GG: Targeting interleukin-4 in asthma: lost in translation? American journal of respiratory cell and molecular biology 2012, 47: 261 -70.
194. Corren J: Anti-interleukin-5 antibody therapy in asthma and allergies. Curr Opin Allergy Clin Immunol 2011, 11: 565-70.
195. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L: lnterleukin-4 receptor in moderate atopic asthma. A phase l/l I randomized, placebo-controlled trial. American journal of respiratory and critical care mediane 1999, 160:1816-23. (Pubitemid 30004681)
196. Nair P, Pizzichini MM, Kjarsgaard M, lnman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. The New England journal of medicine 2009, 360: 985-93.
197. Abonia JP, Putnam PE: Mepolizumab in eosinophilic disorders. Expert review of clinical immunology 2011, 7: 41 1-7.
198. Berry MA, Parker D, Neale N, Woodman L, Morgan A, Monk P, Bradding P, Wardlaw AJ, Pavord ID, Brightling CE: Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. The Journal of allergy and clinical immunology 2004, 114: 1106-9.
199. Park SJ, Lee YC: lnterleukin-17 regulation: an attractive therapeutic approach for asthma. Respiratory research 2010, 11: 78.
200. Nkyimbeng-Takwi EH, Shanks K, Smith E, Iyer A, Lipsky MM, Detolla LJ, Kikutani H, Keegan AD, Chapoval SP: Neuroimmune semaphorin 4A downregulates the severity of allergic response. Mucosal immunology 2012, 5: 409-19.
201. Smith EP, Shanks K, Lipsky MM, DeToIIa LJ, Keegan AD, Chapoval SP: Expression of neuroimmune semaphorins 4A and 4D and their receptors in the lung is enhanced by allergen and vascular endothelial growth factor. BMC immunology 2011, 12: 30.
202. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT: The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. American journal of respiratory and critical care medicine 2006, 174:753-62. (Pubitemid 44511656)
203. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2005, 172:465-9. (Pubitemid 41121991)
204. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J; COPD Investigators: The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2007, 175:926-34. (Pubitemid 46684703)
205. Barnes PJ: Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2007, 175: 866-7.
206. Barnes PJ: The cytokine network in chronic obstructive pulmonary disease. American journal of respiratory cell and molecular biology 2009, 41: 631-8.
207. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nature medicine 2003, 9:669-76. (Pubitemid 36749215)
208. Crawford Y, Ferrara N: VEGF inhibition: insights from preclinical and clinical studies. Cell and tissue research 2009, 335: 261-9.
209. Barnes PJ: The cytokine network in asthma and chronic obstructive pulmonary disease. The Journal of clinical investigation 2008, 118: 3546-56.
210. Wenzel S, Holgate ST: The mouse trap: It still yields few answers in asthma. American journal of respiratory and critical care mediane 2006, 174: 1173-6 discussion 1176-8.
211. Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172: 2731-8.
212. Finkelman FD, Wills-Karp M: Usefulness and optimization of mouse models of allergic airway disease. The Journal of allergy and clinical immunology 2008, 121:603-6. (Pubitemid 351323871)